Claudio Nessi
Partner @ Neomed Management
Geneva, Switzerland
Claudio Nessi is a Series A investor at Neomed Management in Geneva focused on Biotechnology and Health Care. Claudio Nessi joined NeoMed in June 2001 and became a partner in 2004. He has been involved in the creation and early financing of numerous companies in the health care field and has served on the board of directors of Axovan prior to its acquisition by Actelion and PregLem until it was acquired by Gedeon Richter. He became a director ofEndosense in 2005 when he co-led the Series A financing round of the company. He is also currently a director of Kuros Biosurgery and Creabilis. Nessi has completed postdoctoral research work at the Max Planck Institute, Munich, and the University of Connecticut. He received his master’s degree in business administration from the Erasmus University, Rotterdam, and completed a Ph.D. in genetics at the University of Pavia, Italy.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 41%
Last updated:
For AI agents: llms.txt
Industries Claudio Nessi invests in
Stages Claudio Nessi invests in
Countries Claudio Nessi invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 11 (65%)
- Health Care 7 (41%)
- Medical 3 (18%)
- Pharmaceutical 3 (18%)
- Life Science 2 (12%)
Stage
- Series A 6 (35%)
- Series B 3 (18%)
- Series C 3 (18%)
- Post-IPO Equity 2 (12%)
- Series E 1 (6%)
Country
- Switzerland 5 (29%)
- United States 3 (18%)
- Italy 1 (6%)
- Israel 1 (6%)
- Austria 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Alveus Therapeutics
|
Alveus Therapeutics is a clinical-stage biotech company developing therapies for obesity and metabolic diseases. | $197M / Series A / Jan 08, 2026 | |
Spiro Medical
|
Spiro Medical is a medical device company developing a groundbreaking Pulmonary Neuromodulation (PNM) System for asthma treatment. The company offers a drug-free approach to controlling severe, chronic airway diseases through its Spiro Neuromodulation System. | $67M / Series A / Jan 07, 2026 | |
NRG Therapeutics
|
NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and motor neurone disease. Founded in 2018 by a team of experienced biotech and pharmaceutical industryprofessionals, with a background in neuroscience drug discovery, NRG Therapeutics will initially focus on the discovery and development of brain penetrant mitochondrial permeability transition pore inhibitors for the treatment of Parkinson’s disease. | $67.8M / Series B / Sep 08, 2025 | |
SoniVie
|
SoniVie is developing an advanced denervation solution to treat pulmonary hypertension. | $60M / Series C / Jan 09, 2023 | |
|
NRG Therapeutics
|
NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and motor neurone disease. Founded in 2018 by a team of experienced biotech and pharmaceutical industryprofessionals, with a background in neuroscience drug discovery, NRG Therapeutics will initially focus on the discovery and development of brain penetrant mitochondrial permeability transition pore inhibitors for the treatment of Parkinson’s disease. | $18.2M / Series A / Nov 09, 2022 | |
CDR-Life AG
|
CDR-Life is a Zurich-based biotech company that develops innovative therapeutic antibody fragments with a focus on immuno-oncology and ophthalmology. Our facilities are located in the Bio-Technopark in Schlieren-Zurich, Switzerland | $76M / Series A / Apr 13, 2022 | |
Chord Therapeutics
|
Chord Therapeutics is a clinical-stage pharmaceutical company developing drugs for patients with rare, life-threatening, and severely disabling diseases. The company is advancing its lead drug candidate CRD1 under orphan drug designation for the treatment of neuromyelitis optica spectrum disorders (NMOSD) and myasthenia gravis (MG).The companywas founded in 2014 and based in Geneva, Switzerland. | $16M / Series A / Oct 13, 2020 | |
Avitide
|
Avitide develops customized biopharmaceutical affinity purification products with an industry-leading discovery and development service timeline. The Avitide platform reduces process development timelines, program risks, and cost of production by providing high-resolution custom affinity purification solutions.The company was founded in 2012 andis based in Lebanon, New Hampshire. | $12M / Series E / Jun 21, 2017 | |
|
Avitide
|
Avitide develops customized biopharmaceutical affinity purification products with an industry-leading discovery and development service timeline. The Avitide platform reduces process development timelines, program risks, and cost of production by providing high-resolution custom affinity purification solutions.The company was founded in 2012 andis based in Lebanon, New Hampshire. | $7.6M / Series C / Aug 06, 2015 | |
Genkyotex
|
Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases. | $19.7M / Post-IPO Equity / Jan 07, 2015 | |
| See all 17 investments → | |||
Co-Investors
About Neomed Management
NeoMed Management is an international venture capital investment firm, exclusively focused on the healthcare industry. Founded in 1997, NeoMed has established five funds to date.NeoMed invests in emerging companies with outstanding growth prospects. These companies are developing innovative and proprietary medical products that addresssubstantial market opportunities in the pharmaceutical, medical device and diagnostics industries.NeoMed has a multi-stage investment approach and invests at all stages of development from start-up to later stage growth financings. Since inception, NeoMed has successfully invested in more than 30 companies in Europe, including Scandinavia, Switzerland, Germany and the UK, and in North America.From offices in Norway and Switzerland, NeoMed’s experienced investment team works closely with its entrepreneurs and a broader industry network to support the growth of its portfolio companies.NeoMed is currently focusing on NeoMed Innovation IV L.P. and NeoMed Innovation V L.P.
Neomed Management Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Erik Amble
Founder, Chairman & Managing Partner
|
|||
Thomas Goebel
Principal
|
|||
Vincent Ossipow
Partner
|
|||
|
Claudio Nessi
Partner
|
|||
Line B. Westlund
Office Manager
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Claudio Nessi invest in?
Claudio Nessi invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 17 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Claudio Nessi?
Public channels for Claudio Nessi include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Claudio Nessi last invest?
The most recent investment recorded for Claudio Nessi closed in Jan 2026. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
